AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
For more information, visit www.anaptysbio.com.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $73.9M
Founded date: 2005
Investors 3
Funding Rounds 2
Date | Series | Amount | Investors |
15.07.2015 | Series D | $40M | - |
12.11.2007 | - | $33.9M | - |
Mentions in press and media 18
Date | Title | Description | Source |
11.03.2024 | Anaptys Announces Fourth Quarter and Full Year 2023 Financia... | - | globenewsw... |
11.05.2023 | AnaptysBio Announces First Quarter 2023 Financial Results an... | Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a v... | einpresswi... |
12.09.2022 | AnaptysBio Announces Sale of Zejula Royalties for Up To $45 ... | SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biot... | globenewsw... |
25.10.2021 | AnaptysBio Announces Agreement to Monetize Portion of JEMPER... | AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Saga... | globenewsw... |
25.10.2021 | AnaptysBio : Announces Agreement to Monetize Portion of JEMP... | AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Saga... | marketscre... |
11.10.2017 | With just a little encouragement, biotech investors are... | While you may have dealt with VCs during your pre-IPO life, public investors are a whole new lev... | endpts.com... |
07.04.2017 | Candid Truths From A Biotech IPO | Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in bi... | endpts.com... |
27.01.2017 | AnaptysBio's Upsized IPO Raises $75 Million | San Diego biotech AnaptysBio ended up raising $75 million in an upsized initial public offering Jan.... | sdbj.com/n... |
14.09.2015 | Life sciences investor Avalon Ventures raising $300 million ... | The biotech investment landscape has changed, of course, since 2012. On top of that, Avalon has made... | medcitynew... |
15.07.2015 | AnaptysBio Completes $40M Series D Financing | AnaptysBio, Inc., a San Diego, CA-based antibody development company, completed a $40m Series D fina... | finsmes.co... |
Show more